Sodium-glucose cotransporter 2 (SGLT2) inhibitors are the latest therapeutic strategy in the treatment of type 2 diabetes mellitus (T2DM). Using an insulin-independent mechanism (glycosuria), they reduce glucose toxicity and improve insulin sensitivity and β-cell function. The promising results obtained in clinical trials show that SGLT2 significantly improves glycemic control and provides greater cardiovascular protection, combined with a reduction in body weight and blood pressure (BP). This review focuses on ertugliflozin, a new, highly selective, and reversible SGLT2 inhibitor. Clinical trials published to date show that ertugliflozin, both as a monotherapy and as an add-on to oral antidiabetic agents, is safe and effective in reducing glycosylated hemoglobin (HbA1c), body weight, and BP in T2DM patients.

Cinti, F., Moffa, S., Impronta, F., Cefalo, C. M. A., Sun, V. A., Sorice, G., Mezza, T., Giaccari, A., Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: Evidence to date, <<DRUG DESIGN, DEVELOPMENT AND THERAPY>>, 2017; 11 (10): 2905-2919. [doi:10.2147/DDDT.S114932] [http://hdl.handle.net/10807/111697]

Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: Evidence to date

Cinti, Francesca;Moffa, Simona;Impronta, Flavia;Cefalo, Chiara M. A.;Sun, Vinsin A.;Sorice, Gianpio;Mezza, Teresa;Giaccari, Andrea
2017

Abstract

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are the latest therapeutic strategy in the treatment of type 2 diabetes mellitus (T2DM). Using an insulin-independent mechanism (glycosuria), they reduce glucose toxicity and improve insulin sensitivity and β-cell function. The promising results obtained in clinical trials show that SGLT2 significantly improves glycemic control and provides greater cardiovascular protection, combined with a reduction in body weight and blood pressure (BP). This review focuses on ertugliflozin, a new, highly selective, and reversible SGLT2 inhibitor. Clinical trials published to date show that ertugliflozin, both as a monotherapy and as an add-on to oral antidiabetic agents, is safe and effective in reducing glycosylated hemoglobin (HbA1c), body weight, and BP in T2DM patients.
Inglese
Cinti, F., Moffa, S., Impronta, F., Cefalo, C. M. A., Sun, V. A., Sorice, G., Mezza, T., Giaccari, A., Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: Evidence to date, <<DRUG DESIGN, DEVELOPMENT AND THERAPY>>, 2017; 11 (10): 2905-2919. [doi:10.2147/DDDT.S114932] [http://hdl.handle.net/10807/111697]
File in questo prodotto:
File Dimensione Formato  
dddt-11-2905.pdf

accesso aperto

Tipologia file ?: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 718.81 kB
Formato Adobe PDF
718.81 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/111697
Citazioni
  • ???jsp.display-item.citation.pmc??? 17
  • Scopus 39
  • ???jsp.display-item.citation.isi??? 39
social impact